Dr. Joseph Francis McLaughlin, MD
- Medicare services, 2024
- 39,205
- Medicare patients, 2024
- 498
- Part D claims, 2024
- 2,243
- Publications
- 6
- Clinical trials
- 5
- Practice address
- 500 Frank W Burr Blvd, Teaneck, NJ 07666
- Practice phone
- Call (860) 533-3091
- Professional email
- Get professional email
- Personal email
- Get personal email
- Mobile number
- Get mobile number
Primary practice
Regional Cancer Care Associates
Teaneck, New Jersey
Find Dr. McLaughlin's professional email, personal email and mobile number
Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.
Dr. Joseph Francis McLaughlin is a medical oncologist in Teaneck, New Jersey
Dr. McLaughlin practices at Regional Cancer Care Associates in Teaneck, New Jersey.
Dr. McLaughlin's NPI, 1013178466, was assigned on June 18, 2008. Dr. McLaughlin holds Connecticut license 49687.
- NPI
- 1013178466NPI Registry (opens in a new tab)
- Medicare PAC ID
- 7416279856
- NPI enumeration date
- June 18, 2008
- NPI status
- Active
- Accepts Medicare assignment
- Yes
- Practice phone
- (860) 533-3091
- Professional email
- Get email
- Personal email
- Get email
- Mobile number
- Get number
- Sex
- Male
- Estimated age
- 44
- Medical school graduation
- 2008
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; Dmand AI Practice Data; and Doctors and Clinicians National Downloadable File (CMS)
Dr. Joseph Francis McLaughlin practices at Regional Cancer Care Associates in Teaneck, New Jersey
Dr. McLaughlin's primary practice is Regional Cancer Care Associates, at 500 Frank W Burr Blvd, Teaneck, NJ 07666 in Bergen County. The practice phone is (860) 533-3091.
- Regional Cancer Care Associates500 Frank W Burr Blvd, Teaneck, NJ 07666 · Bergen CountyPhone(860) 533-3091
Sources: NPPES NPI Registry (CMS); and Dmand AI Practice Data
Dr. Joseph Francis McLaughlin is affiliated with 9 sites of care and 1 medical group
Dr. McLaughlin's primary practice is Regional Cancer Care Associates in Teaneck, New Jersey. Dr. McLaughlin is also affiliated with Manchester Memorial Hospital. The medical group on file is Regional Cancer Care Associates. Dmand AI also links Dr. McLaughlin to 1 more hospital, 2 home health agencies, 2 hospices, 1 physician office and 1 group practice or clinic, each named with a free account.
Sources: NPPES NPI Registry (CMS); Dmand AI Practice Data; and Dmand AI Affiliation Data
Dmand AI tracks the EHR system at Dr. Joseph Francis McLaughlin's practice
Dmand AI tracks the electronic health record (EHR) system at each site where Dr. McLaughlin practices, 8 sites in all. Vendor and product names are available with a free account.
| Site | EHR vendor and product |
|---|---|
| Regional Cancer Care Associates | Available with a free account |
| +8 more affiliated sites | Available with a free account |
Source: Dmand AI Technology Install Data
For health IT teams
Dmand AI maps EHR vendors, IT decision makers and buying committees across each health system and 6.2K+ hospitals, with verified contacts in the same login.
Dr. Joseph Francis McLaughlin is one of 115 medical oncologists in New Jersey
Medical oncology is Dr. McLaughlin's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. McLaughlin is licensed in Connecticut.
Specialties and state licenses
- Medical oncology, ConnecticutPrimary
Medical oncologists near Dr. McLaughlin
Counts of medical oncologists with a Dmand AI profile, by place and practice. Each opens the list.
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks
Dr. Joseph Francis McLaughlin billed Medicare for 39,205 services in 2024
CMS data shows 39,205 Medicare services from Dr. McLaughlin across 30 procedure codes in 2024, for 498 Medicare patients. Medicare paid $999,686 for them.
Dr. McLaughlin's Medicare services by type, 2023 to 2024
- 2023
- 2024
- Drugs given in the office
- 2023: 21,2892024: 35,48667%
- Tests and treatments
- 2023: 1,4552024: 2,18450%
- Office and hospital visits
- 2023: 1,0152024: 1,51850%
- Surgery
- 2023: 02024: 17
- Other services
- 2023: 5402024: 0100%
Where Dr. McLaughlin's Medicare services took place, 2024
- In an office39,147100%
- In a facility580%
Dr. McLaughlin compared with the New Jersey median for medical oncologists, 2024
- Dr. McLaughlin
- New Jersey median
- Medicare services
- 39,205vs 72354.2 times
- Medicare patients
- 498vs 2322.1 times
- Part D claims
- 1,952vs 3595.4 times
Medians across 107 medical oncologists in New Jersey with Dmand AI profiles that report each measure.
Dr. McLaughlin's most billed Medicare procedure codes, 2024
CMS publishes codes billed for 11 or more Medicare patients. Each label is the code family; CPT descriptions are licensed by the AMA.
Need commercial claims for Dr. McLaughlin?
Medicare shows one payer. Book a meeting to get commercial claims data for Dr. McLaughlin and other medical oncologists in New Jersey.
Sources: Medicare Physician & Other Practitioners - by Provider and Service (CMS), 2024 data; and Dmand AI Peer Benchmarks
Dr. Joseph Francis McLaughlin treated 498 Medicare patients in 2024, average age 76
CMS counts 498 Medicare patients who saw Dr. McLaughlin in 2024. The largest group is 75 to 84, with 195 patients. 75% of them have high cholesterol, and 74% have high blood pressure. 23% are also on Medicaid. Their average risk score is 1.97, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.
Across all payers, Dmand AI patient panel data puts Dr. McLaughlin's median patient age at 74, with 61% women.
Dr. McLaughlin's Medicare patients by age, 2024
Dr. McLaughlin's Medicare patients by sex, 2024
- Women28056%
- Men21844%
Chronic conditions among Dr. McLaughlin's Medicare patients, 2024
- High cholesterol75%
- High blood pressure74%
- Cancer43%
- Arthritis38%
- Diabetes36%
- Ischemic heart disease32%
- Chronic kidney disease29%
- Anxiety26%
Share of Medicare patients with each condition. A patient can have several.
Dr. McLaughlin's patients across all payers
Dmand AI patient panel data covers Medicare, Medicaid and commercial patients.
Patient panel by age, all payers
Median age 74
Patient panel by sex, all payers
- Women61%
- Men37%
Sources: Dmand AI Patient Panel Data; and Medicare Physician & Other Practitioners - by Provider (CMS), 2024 data
Dr. Joseph Francis McLaughlin wrote 2,243 Medicare Part D claims in 2024
In 2024, Dr. McLaughlin wrote 2,243 Medicare Part D claims for 348 patients. 69% of them were for generic drugs. CMS names the drug for 1,952 of them, across 36 drugs with 11 or more claims each, at $6,526,090 in total drug cost. In 2023, CMS named 1,622 claims across 31 drugs.
Dr. McLaughlin's Part D claims by kind of drug, 2024
- Generic1,539 claims69%
- Brand-name704 claims31%
Dr. McLaughlin's most prescribed drugs by claims, 2024
CMS names a drug when it has 11 or more claims. Share is of the claims for drugs CMS names.
Drug classes CMS tracks in Dr. McLaughlin's Part D claims, 2024
- Opioids3%57 of 2,243 claims
- Antibiotics1%29 of 2,243 claims
Share of all Part D claims for each drug class CMS reports on. Classes with no claims are left out.
Part D claims for drugs CMS names, 2023 to 2024
- 2023
- 2024
- Claims for drugs CMS names
- 2023: 1,6222024: 1,95220%
Drugs named by CMS: 36 in 2024, 31 in 2023.
Sources: Medicare Part D Prescribers - by Provider and Drug (CMS), 2024 data, released May 6, 2026; and Medicare Part D Prescribers - by Provider (CMS), 2024 data
Dr. Joseph Francis McLaughlin scored 91 out of 100 in Medicare's MIPS program for 2024
CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. McLaughlin for performance year 2024, reported individually. Dr. McLaughlin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.
- Accepts Medicare assignment
- Yes
Dr. McLaughlin's MIPS scores, performance year 2024
- 91of 100Final score
- 71.8of 100Quality
- 100of 100Promoting Interoperability
- 40of 100Improvement Activities
Each score is out of 100. The final score weighs the categories CMS scored for this clinician.
Sources: Doctors and Clinicians National Downloadable File (CMS); and Clinician Public Reporting: Overall MIPS Performance (CMS), 2024 data, released September 10, 2026
For MedTech and pharma teams
Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.
Dr. Joseph Francis McLaughlin has 6 publications on record
Dmand AI links 6 papers to Dr. McLaughlin, published from 2015 to 2016. 2016 was the busiest year, with 3. The most frequent topics are Lung Neoplasms, Biomarkers, Tumor and Carcinoma, Non-Small-Cell Lung. Dr. McLaughlin's most frequent co-authors are Vamsidhar Velcheti, MD, Mehmet Altan, MD and Brian Samuel Henick, MD.
Topics Dr. McLaughlin writes about most
- Lung Neoplasms
- Biomarkers, Tumor
- Carcinoma, Non-Small-Cell Lung
- Immunohistochemistry
Dr. McLaughlin's most frequent co-authors
- Vamsidhar Velcheti, MD3 shared papers
- Mehmet Altan, MD2 shared papers
- Brian Samuel Henick, MD1 shared paper
Recent publications by Dr. McLaughlin
See who Dr. McLaughlin researches with
Physician Network Discovery turns co-authorship, shared hospitals and shared groups into a map of who Dr. McLaughlin works with, so you can find a warm path to the right medical oncologists.
Sources: PubMed (National Library of Medicine); and Dmand AI Research Linkage
Dr. Joseph Francis McLaughlin has worked on 5 clinical trials
Dmand AI links Dr. McLaughlin to 5 clinical trials, 3 of them phase 3 studies. 5 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Biliary Tract Neoplasms. National Cancer Institute (NCI) sponsors the most, 3.
Clinical trials with Dr. McLaughlin by phase
- NonePhase 1: no trials
- 1Phase 2: 1 trial
- 3Phase 3: 3 trials
- NonePhase 4: no trials
Conditions in Dr. McLaughlin's trials
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Bronchogenic
- Biliary Tract Neoplasms
- Uterine Cervical Neoplasms
Investigators on the most trials with Dr. McLaughlin
- Sheetal Sumat Acharya, MD4 shared trials
- Joseph Aisner4 shared trials
- Spencer Henick Bachow, MD4 shared trials
Recent clinical trials with Dr. McLaughlin
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations (opens in a new tab)
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) (opens in a new tab)
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) (opens in a new tab)
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) (opens in a new tab)
Sources: Dmand AI Research Linkage; and ClinicalTrials.gov (National Library of Medicine)
Dr. Joseph Francis McLaughlin received $251,614 in industry payments from 2016 to 2025
CMS Open Payments shows 438 general payments to Dr. McLaughlin from 47 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 87% of the total. Bristol-Myers Squibb Company paid the most, $241,249.
General payments to Dr. McLaughlin by program year, 2016 to 2025
General payments to Dr. McLaughlin by kind, 2016 to 2025
- Speaker and faculty fees$219,07987%
- Consulting fees$21,7749%
- Food and beverage$8,4453%
- Travel and lodging$1,8811%
- Education$4350%
Companies that paid Dr. McLaughlin the most, 2016 to 2025
Share is of all general payments to this clinician.
Source: Open Payments (CMS), 2025 data, released July 7, 2026
Sources for Dr. Joseph Francis McLaughlin's profile data
Data last refreshed October 2026Report an inaccuracyRemove my information
FAQ
Frequently asked questions about Dr. Joseph Francis McLaughlin
Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.
What is Dr. Joseph Francis McLaughlin's NPI number?
Dr. Joseph Francis McLaughlin's NPI number is 1013178466. It was assigned on June 18, 2008, and it is active in the NPI Registry.
What kind of doctor is Dr. Joseph Francis McLaughlin?
Dr. Joseph Francis McLaughlin is a medical oncologist in Teaneck, New Jersey. The primary specialty in the NPI Registry is Medical Oncology Physician (taxonomy code 207RX0202X).
Where does Dr. Joseph Francis McLaughlin practice?
Dr. McLaughlin practices at 500 Frank W Burr Blvd, Teaneck, NJ 07666. Dr. McLaughlin's primary practice is Regional Cancer Care Associates in Teaneck, New Jersey. Dmand AI also links Dr. McLaughlin to 1 hospital, 2 home health agencies, 2 hospices, 1 physician office and 1 group practice or clinic.
What is Dr. Joseph Francis McLaughlin's office phone number?
The practice phone on file for Dr. McLaughlin is (860) 533-3091.
What is Dr. Joseph Francis McLaughlin's medical license number?
Dr. McLaughlin holds Connecticut license 49687.
Which hospitals is Dr. Joseph Francis McLaughlin affiliated with?
Dr. McLaughlin is affiliated with Manchester Memorial Hospital. Dmand AI links Dr. McLaughlin to 1 more hospital.
What medical group is Dr. Joseph Francis McLaughlin part of?
Dr. McLaughlin is linked to Regional Cancer Care Associates.
Does Dr. Joseph Francis McLaughlin accept Medicare?
Yes. CMS data shows Dr. McLaughlin billed Medicare for 39,205 services in 2024, and Dr. McLaughlin accepts Medicare assignment.
What is Dr. Joseph Francis McLaughlin's MIPS score?
Dr. McLaughlin's MIPS final score for performance year 2024 is 91 out of 100, reported individually.
How many Medicare patients does Dr. Joseph Francis McLaughlin see?
CMS counts 498 Medicare patients who saw Dr. McLaughlin in 2024, with an average age of 76.
Show 6 more questionsShow fewer questions
What services does Dr. Joseph Francis McLaughlin bill to Medicare?
In 2024, Dr. McLaughlin's most billed Medicare services were injected or infused drug (J9271), injected or infused drug (J0185) and injected or infused drug (J0897).
What drugs does Dr. Joseph Francis McLaughlin prescribe most?
In 2024 Medicare Part D data, Dr. McLaughlin's most prescribed drugs by claims were Anastrozole, Abiraterone Acetate and Prednisone.
Has Dr. Joseph Francis McLaughlin received payments from drug or device companies?
CMS Open Payments shows $251,614 in general payments to Dr. McLaughlin from 47 companies from 2016 to 2025. The largest total came from Bristol-Myers Squibb Company.
How long has Dr. Joseph Francis McLaughlin been practicing?
Dr. McLaughlin graduated from medical school in 2008, 18 years ago.
Does Dr. Joseph Francis McLaughlin do research?
Dmand AI links 6 publications to Dr. McLaughlin, published from 2015 to 2016. Dr. McLaughlin has worked on 5 clinical trials.
Who does Dr. Joseph Francis McLaughlin publish with?
Dr. McLaughlin's most frequent co-authors are Vamsidhar Velcheti, MD (3 shared papers), Mehmet Altan, MD (2 shared papers) and Brian Samuel Henick, MD (1 shared paper).
Selling to medical oncology practices?
See medical oncologists in New Jersey by site of care and group
Find the practices, groups and hospitals they work with, and the right people to contact at each.
- 30 days free
- Self-serve
- No credit card